Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Kim, JC; Steinberg, GD
   Medical management of patients with refractory carcinoma in situ of the bladder
   DRUGS & AGING
   
   J.C. Kim e G.D. Steinberg, "Medical management of patients with refractory carcinoma in situ of the bladder", DRUG AGING, 18(5), 2001, pp. 335-344
2. Bernardini, S; Chabannes, E; Bittard, H
   Value of p53 in the clinical management of bladder cancer.
   PROGRES EN UROLOGIE
   
   S. Bernardini et al., "Value of p53 in the clinical management of bladder cancer.", PROG UROL, 11(2), 2001, pp. 201-208
3. Kuromatsu, I; Matsuo, K; Takamura, S; Kim, G; Takebe, Y; Kawamura, J; Yasutomi, Y
   Induction of effective antitumor immune responses in a mouse bladder tumormodel by using DNA of an alpha antigen from mycobacteria
   CANCER GENE THERAPY
   
   I. Kuromatsu et al., "Induction of effective antitumor immune responses in a mouse bladder tumormodel by using DNA of an alpha antigen from mycobacteria", CANC GENE T, 8(7), 2001, pp. 483-490
4. Sekine, H; Ohya, K; Kojima, S; Igarashi, K; Fukui, I
   Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder
   INTERNATIONAL JOURNAL OF UROLOGY
   
   H. Sekine et al., "Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder", INT J UROL, 8(9), 2001, pp. 483-486
5. Baselli, EC; Greenberg, RE
   Maintenance therapy for superficial bladder cancer
   ONCOLOGY-NEW YORK
   
   E.C. Baselli e R.E. Greenberg, "Maintenance therapy for superficial bladder cancer", ONCOLOGY-NY, 15(1), 2001, pp. 85-88
6. Bochner, BH; Skinner, DG
   Maintenance therapy for superficial bladder cancer - The Baselli/Greenbergarticle reviewed
   ONCOLOGY-NEW YORK
   
   B.H. Bochner e D.G. Skinner, "Maintenance therapy for superficial bladder cancer - The Baselli/Greenbergarticle reviewed", ONCOLOGY-NY, 15(1), 2001, pp. 90-91
7. Jocham, D; Durek, C
   Treatment of superficial tumors of the urinary bladder
   UROLOGE A
   
   D. Jocham e C. Durek, "Treatment of superficial tumors of the urinary bladder", UROLOGE A, 40(6), 2001, pp. 460-463
8. Kim, JC; Steinberg, GD
   The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder
   JOURNAL OF UROLOGY
   
   J.C. Kim e G.D. Steinberg, "The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder", J UROL, 165(3), 2001, pp. 745-756
9. Choudry, GA; Stewart, PAH; Double, JA; Krul, MRL; Naylor, B; Flannigan, GM; Shah, TK; Brown, JE; Phillips, RM
   A novel strategy for NQO1 (NAD(P)H : quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9
   BRITISH JOURNAL OF CANCER
   
   G.A. Choudry et al., "A novel strategy for NQO1 (NAD(P)H : quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9", BR J CANC, 85(8), 2001, pp. 1137-1146
10. Lamm, DL
    Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer
    CLINICAL INFECTIOUS DISEASES
    
    D.L. Lamm, "Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer", CLIN INF D, 31, 2000, pp. S86-S90
11. Audigier, C; Nesme, P; Perol, M; Guerin, JC
    A rare lung complication of intra-bladder BCG therapy
    REVUE DES MALADIES RESPIRATOIRES
    
    C. Audigier et al., "A rare lung complication of intra-bladder BCG therapy", REV MAL RES, 17(3), 2000, pp. 679-681
12. Lamm, DL; Allaway, M
    Current trends in bladder cancer treatment
    ANNALES CHIRURGIAE ET GYNAECOLOGIAE
    
    D.L. Lamm e M. Allaway, "Current trends in bladder cancer treatment", ANN CHIR GY, 89(3), 2000, pp. 234-241
13. Schmitz-Drager, BJ; Goebell, PJ; Ebert, T; Fradet, Y
    p53 immunohistochemistry as a prognostic marker in bladder cancer - Playground for urology scientists?
    EUROPEAN UROLOGY
    
    B.J. Schmitz-Drager et al., "p53 immunohistochemistry as a prognostic marker in bladder cancer - Playground for urology scientists?", EUR UROL, 38(6), 2000, pp. 691-699
14. Linn, JF; Black, P; Derksen, K; Rubben, H; Thuroff, JW
    Keyhole limpet haemocyanin in experimental bladder cancer
    EUROPEAN UROLOGY
    
    J.F. Linn et al., "Keyhole limpet haemocyanin in experimental bladder cancer", EUR UROL, 37, 2000, pp. 34-40
15. Jurincic-Winkler, CD; Metz, KA; Beuth, J; Klippel, KF
    Keyhole limpet hemocyanin for carcinoma in situ of the bladder: A long-term follow-up study
    EUROPEAN UROLOGY
    
    C.D. Jurincic-Winkler et al., "Keyhole limpet hemocyanin for carcinoma in situ of the bladder: A long-term follow-up study", EUR UROL, 37, 2000, pp. 45-49
16. Bohle, A
    BCG's mechanism of action - Increasing our understanding
    EUROPEAN UROLOGY
    
    A. Bohle, "BCG's mechanism of action - Increasing our understanding", EUR UROL, 37, 2000, pp. 1-8
17. Lamm, DL
    Preventing progression and improving survival with BCG maintenance
    EUROPEAN UROLOGY
    
    D.L. Lamm, "Preventing progression and improving survival with BCG maintenance", EUR UROL, 37, 2000, pp. 9-15
18. Malmstrom, PU
    Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience
    EUROPEAN UROLOGY
    
    P.U. Malmstrom, "Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience", EUR UROL, 37, 2000, pp. 16-20
19. Durek, C; Rusch-Gerdes, S; Jocham, D; Bohle, A
    Sensitivity of BCG to modern antibiotics
    EUROPEAN UROLOGY
    
    C. Durek et al., "Sensitivity of BCG to modern antibiotics", EUR UROL, 37, 2000, pp. 21-25
20. Rischmann, P; Desgrandchamps, F; Malavaud, B; Chopin, DK
    BCG intravesical instillations: Recommendations for side-effects management
    EUROPEAN UROLOGY
    
    P. Rischmann et al., "BCG intravesical instillations: Recommendations for side-effects management", EUR UROL, 37, 2000, pp. 33-36
21. Khandaker, MH; Kadhim, SA; Ichim, TE; Howson-Jan, K; Chin, J; Singhal, SK
    Prevention of bladder tumor formation in mice by a novel bone marrow-derived factor, reptimed
    ANTICANCER RESEARCH
    
    M.H. Khandaker et al., "Prevention of bladder tumor formation in mice by a novel bone marrow-derived factor, reptimed", ANTICANC R, 20(1A), 2000, pp. 183-189
22. Marchetti, A; Wang, LP; Magar, R; Grossman, HB; Lamm, DL; Schellhammer, PF; Erwin-Toth, P
    Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: Cost implications of a clinical trial for valrubicin
    CLINICAL THERAPEUTICS
    
    A. Marchetti et al., "Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: Cost implications of a clinical trial for valrubicin", CLIN THER, 22(4), 2000, pp. 422-438
23. Zlotta, AR; Schulman, CC
    Biological markers in superficial bladder tumors and their prognostic significance
    UROLOGIC CLINICS OF NORTH AMERICA
    
    A.R. Zlotta e C.C. Schulman, "Biological markers in superficial bladder tumors and their prognostic significance", UROL CLIN N, 27(1), 2000, pp. 179
24. Zhang, GJ; Crist, SA; McKerrow, AK; Xu, Y; Ladehoff, DC; See, WA
    Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the alpha 5 beta 1 fibronectin receptor
    JOURNAL OF UROLOGY
    
    G.J. Zhang et al., "Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the alpha 5 beta 1 fibronectin receptor", J UROL, 163(5), 2000, pp. 1553-1559
25. Knemeyer, I; Wientjes, MG; Au, JLS
    Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    I. Knemeyer et al., "Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment", CANC CHEMOT, 44(3), 1999, pp. 241-248
26. Crew, JP
    Vascular endothelial growth factor: An important angiogenic mediator in bladder cancer
    EUROPEAN UROLOGY
    
    J.P. Crew, "Vascular endothelial growth factor: An important angiogenic mediator in bladder cancer", EUR UROL, 35(1), 1999, pp. 2-8
27. Syrigos, KN; Deonarian, DP; Epenetos, AA
    Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer
    HYBRIDOMA
    
    K.N. Syrigos et al., "Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer", HYBRIDOMA, 18(3), 1999, pp. 219-224
28. Hurle, R; Losa, A; Manzetti, A; Lembo, A
    Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients
    UROLOGY
    
    R. Hurle et al., "Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients", UROLOGY, 53(6), 1999, pp. 1144-1148
29. Durek, C; Rusch-Gerdes, S; Jocham, D; Bohle, A
    Interference of modern antibacterials with bacillus Calmette-Guerin viability
    JOURNAL OF UROLOGY
    
    C. Durek et al., "Interference of modern antibacterials with bacillus Calmette-Guerin viability", J UROL, 162(6), 1999, pp. 1959-1962
30. Pfister, C; Flaman, JM; Dunet, F; Grise, P; Frebourg, T
    p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy
    JOURNAL OF UROLOGY
    
    C. Pfister et al., "p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy", J UROL, 162(1), 1999, pp. 69-73
31. Di Stasi, SM; Giannantoni, A; Massoud, R; Dolci, S; Navarra, P; Vespasiani, G; Stephen, RL
    Electromotive versus passive diffusion of mitomycin C into human bladder wall: Concentration-depth profiles studies
    CANCER RESEARCH
    
    S.M. Di Stasi et al., "Electromotive versus passive diffusion of mitomycin C into human bladder wall: Concentration-depth profiles studies", CANCER RES, 59(19), 1999, pp. 4912-4918
32. NSEYO UO; DEHAVEN J; DOUGHERTY TJ; POTTER WR; MERRILL DL; LUNDAHL SL; LAMM DL
    PHOTODYNAMIC THERAPY (PDT) IN THE TREATMENT OF PATIENTS WITH RESISTANT SUPERFICIAL BLADDER-CANCER - A LONG-TERM EXPERIENCE
    Journal of clinical laser medicine & surgery
    
    U.O. Nseyo et al., "PHOTODYNAMIC THERAPY (PDT) IN THE TREATMENT OF PATIENTS WITH RESISTANT SUPERFICIAL BLADDER-CANCER - A LONG-TERM EXPERIENCE", Journal of clinical laser medicine & surgery, 16(1), 1998, pp. 61-68
33. LEBRET T; GAUDEZ F; HERVE JM; BARRE P; LUGAGNE PM; BOTTO H
    LOW-DOSE BCG INSTILLATIONS IN THE TREATMENT OF STAGE T1 GRADE 3 BLADDER-TUMORS - RECURRENCE, PROGRESSION AND SUCCESS
    European urology
    
    T. Lebret et al., "LOW-DOSE BCG INSTILLATIONS IN THE TREATMENT OF STAGE T1 GRADE 3 BLADDER-TUMORS - RECURRENCE, PROGRESSION AND SUCCESS", European urology, 34(1), 1998, pp. 67-72
34. SOLOMON LZ; JENNINGS AM; HAYES MC; BASS PS; BIRCH BR; COOPER AJ
    IS GAMMA-LINOLENIC ACID AN EFFECTIVE INTRAVESICAL AGENT FOR SUPERFICIAL BLADDER-CANCER - IN-VITRO CYTOTOXICITY AND IN-VIVO TOLERANCE STUDIES
    Urological research
    
    L.Z. Solomon et al., "IS GAMMA-LINOLENIC ACID AN EFFECTIVE INTRAVESICAL AGENT FOR SUPERFICIAL BLADDER-CANCER - IN-VITRO CYTOTOXICITY AND IN-VIVO TOLERANCE STUDIES", Urological research, 26(1), 1998, pp. 11-15
35. SOLOMON LZ; JENNINGS AM; SHARPE P; COOPER AJ; BIRCH BR
    INTRAVESICAL CHEMOTHERAPY WITH GAMMA-LINOLENIC ACID BECOMES A REALISTIC PROSPECT IN SERUM-FREE APPLICATIONS - IN-VITRO CYTOTOXICITY AND SYSTEMIC ABSORPTION STUDIES
    The Journal of urology
    
    L.Z. Solomon et al., "INTRAVESICAL CHEMOTHERAPY WITH GAMMA-LINOLENIC ACID BECOMES A REALISTIC PROSPECT IN SERUM-FREE APPLICATIONS - IN-VITRO CYTOTOXICITY AND SYSTEMIC ABSORPTION STUDIES", The Journal of urology, 160(6), 1998, pp. 2280-2283
36. BUYSE G; WALDECK K; VERPOORTEN C; BJORK H; CASAER P; ANDERSSON KE
    INTRAVESICAL OXYBUTYNIN FOR NEUROGENIC BLADDER DYSFUNCTION - LESS SYSTEMIC SIDE-EFFECTS DUE TO REDUCED FIRST PASS METABOLISM
    The Journal of urology
    
    G. Buyse et al., "INTRAVESICAL OXYBUTYNIN FOR NEUROGENIC BLADDER DYSFUNCTION - LESS SYSTEMIC SIDE-EFFECTS DUE TO REDUCED FIRST PASS METABOLISM", The Journal of urology, 160(3), 1998, pp. 892-896
37. BELLDEGRUN AS; FRANKLIN JR; ODONNELL MA; GOMELLA LG; KLEIN E; NERI R; NSEYO UO; RATLIFF TL; WILLIAMS RD
    SUPERFICIAL BLADDER-CANCER - THE ROLE OF INTERFERON-ALPHA
    The Journal of urology
    
    A.S. Belldegrun et al., "SUPERFICIAL BLADDER-CANCER - THE ROLE OF INTERFERON-ALPHA", The Journal of urology, 159(6), 1998, pp. 1793-1801
38. MUNGAN NA; WITJES JA
    BACILLE CALMETTE-GUERIN IN SUPERFICIAL TRANSITIONAL-CELL CARCINOMA
    British Journal of Urology
    
    N.A. Mungan e J.A. Witjes, "BACILLE CALMETTE-GUERIN IN SUPERFICIAL TRANSITIONAL-CELL CARCINOMA", British Journal of Urology, 82(2), 1998, pp. 213-223
39. NSEYO UO; LAMM DL
    IMMUNOTHERAPY OF BLADDER-CANCER
    Seminars in surgical oncology
    
    U.O. Nseyo e D.L. Lamm, "IMMUNOTHERAPY OF BLADDER-CANCER", Seminars in surgical oncology, 13(5), 1997, pp. 342-349
40. UCHIDA T; EGAWA S; IWAMURA M; OHKAWA A; ENDO T; KOSHIBA K
    3-DAY INTRAVESICAL INSTILLATION OF ANTICANCER DRUGS FOR PROPHYLAXIS OF BLADDER-CANCER
    Oncology Reports
    
    T. Uchida et al., "3-DAY INTRAVESICAL INSTILLATION OF ANTICANCER DRUGS FOR PROPHYLAXIS OF BLADDER-CANCER", Oncology Reports, 4(3), 1997, pp. 573-577
41. SERELS S; FLEISCHMANN J
    BIOLOGIC RESPONSE MODIFIERS IN THE MANAGEMENT OF SUPERFICIAL BLADDER-CANCER
    World journal of urology
    
    S. Serels e J. Fleischmann, "BIOLOGIC RESPONSE MODIFIERS IN THE MANAGEMENT OF SUPERFICIAL BLADDER-CANCER", World journal of urology, 15(2), 1997, pp. 96-102
42. HUGHES ODM; BISHOP MC; PERKINS AC; FRIER M; PRICE MR; DENTON G; SMITH A; RUTHERFORD R; SCHUBIGER PA
    PRECLINICAL EVALUATION OF COPPER-67 LABELED ANTI-MUC1 MUCIN ANTIBODY C595 FOR THERAPEUTIC USE IN BLADDER-CANCER
    European journal of nuclear medicine
    
    O.D.M. Hughes et al., "PRECLINICAL EVALUATION OF COPPER-67 LABELED ANTI-MUC1 MUCIN ANTIBODY C595 FOR THERAPEUTIC USE IN BLADDER-CANCER", European journal of nuclear medicine, 24(4), 1997, pp. 439-443
43. MARTINEZPINEIRO JA; MARTINEZPINEIRO L
    BCG UPDATE - INTRAVESICAL THERAPY
    European urology
    
    J.A. Martinezpineiro e L. Martinezpineiro, "BCG UPDATE - INTRAVESICAL THERAPY", European urology, 31, 1997, pp. 31-41
44. CHANG SC; BUONACCORSI G; MACROBERT AJ; BOWN SG
    5-AMINOLEVULINIC ACID (ALA)-INDUCED PROTOPORPHYRIN-IX FLUORESCENCE AND PHOTODYNAMIC EFFECTS IN THE RAT BLADDER - AN IN-VIVO STUDY COMPARINGORAL AND INTRAVESICAL ALA ADMINISTRATION
    Lasers in surgery and medicine
    
    S.C. Chang et al., "5-AMINOLEVULINIC ACID (ALA)-INDUCED PROTOPORPHYRIN-IX FLUORESCENCE AND PHOTODYNAMIC EFFECTS IN THE RAT BLADDER - AN IN-VIVO STUDY COMPARINGORAL AND INTRAVESICAL ALA ADMINISTRATION", Lasers in surgery and medicine, 20(3), 1997, pp. 254-264
45. COOKSON MS; HERR HW; ZHANG ZF; SOLOWAY S; SOGANI PC; FAIR WR
    THE TREATED NATURAL-HISTORY OF HIGH-RISK SUPERFICIAL BLADDER-CANCER -15-YEAR OUTCOME
    The Journal of urology
    
    M.S. Cookson et al., "THE TREATED NATURAL-HISTORY OF HIGH-RISK SUPERFICIAL BLADDER-CANCER -15-YEAR OUTCOME", The Journal of urology, 158(1), 1997, pp. 62-67
46. DISTASI SM; VESPASIANI G; GIANNANTONI A; MASSOUD R; DOLCI S; MICALI F
    ELECTROMOTIVE DELIVERY OF MITOMYCIN-C INTO HUMAN BLADDER WALL
    Cancer research
    
    S.M. Distasi et al., "ELECTROMOTIVE DELIVERY OF MITOMYCIN-C INTO HUMAN BLADDER WALL", Cancer research, 57(5), 1997, pp. 875-880
47. ALIELDEIN B; NABEEH A; ELBAZ M; SHAMAA S; ASHAMALLAH A
    SINGLE-DOSE VERSUS MULTIPLE INSTILLATIONS OF EPIRUBICIN AS PROPHYLAXIS FOR RECURRENCE AFTER TRANSURETHRAL RESECTION OF PTA AND PT1 TRANSITIONAL-CELL BLADDER-TUMORS - A PROSPECTIVE, RANDOMIZED CONTROLLED-STUDY
    British Journal of Urology
    
    B. Alieldein et al., "SINGLE-DOSE VERSUS MULTIPLE INSTILLATIONS OF EPIRUBICIN AS PROPHYLAXIS FOR RECURRENCE AFTER TRANSURETHRAL RESECTION OF PTA AND PT1 TRANSITIONAL-CELL BLADDER-TUMORS - A PROSPECTIVE, RANDOMIZED CONTROLLED-STUDY", British Journal of Urology, 79(5), 1997, pp. 731-735
48. HOLLAND AJA; KING PA; CHAUVEL PJ; ONEILL MK; MCKNIGHT DL; BARKER AP
    INTRAVESICAL THERAPY FOR THE TREATMENT OF NEUROGENIC BLADDER IN CHILDREN
    Australian and New Zealand journal of surgery
    
    A.J.A. Holland et al., "INTRAVESICAL THERAPY FOR THE TREATMENT OF NEUROGENIC BLADDER IN CHILDREN", Australian and New Zealand journal of surgery, 67(10), 1997, pp. 731-733
49. STENZL A; EDER I; KOSTRON H; KLOCKER H; BARTSCH G
    ELECTROMOTIVE DIFFUSION (EMD) AND PHOTODYNAMIC THERAPY WITH DELTA-AMINOLEVULINIC-ACID (DELTA-ALA) FOR SUPERFICIAL BLADDER-CANCER
    Journal of photochemistry and photobiology.B, Biology
    
    A. Stenzl et al., "ELECTROMOTIVE DIFFUSION (EMD) AND PHOTODYNAMIC THERAPY WITH DELTA-AMINOLEVULINIC-ACID (DELTA-ALA) FOR SUPERFICIAL BLADDER-CANCER", Journal of photochemistry and photobiology.B, Biology, 36(2), 1996, pp. 233-236
50. SINGH SS; SMITH KM; BROWN DM
    DRUG RETENTION FOLLOWING INTRAVESICAL DELIVERY OF FLUOROURACIL THERAPEUTIC ADHESIVE IN C3H MOUSE BLADDER
    Anti-cancer drugs
    
    S.S. Singh et al., "DRUG RETENTION FOLLOWING INTRAVESICAL DELIVERY OF FLUOROURACIL THERAPEUTIC ADHESIVE IN C3H MOUSE BLADDER", Anti-cancer drugs, 7(5), 1996, pp. 507-513
51. JUNG P; JAKSE G
    BLADDER PRESERVATION IN INVASIVE LOCALLY CONFINED BLADDER-CANCER
    Onkologie
    
    P. Jung e G. Jakse, "BLADDER PRESERVATION IN INVASIVE LOCALLY CONFINED BLADDER-CANCER", Onkologie, 19(4), 1996, pp. 296-301
52. PERNOT M; HUBERT J; GUILLEMIN F; SIX A; HOFFSTETTER S; PEIFFERT D; VERHAEGHE J; LUPORSI E
    COMBINED SURGERY AND BRACHYTHERAPY IN THE TREATMENT OF SOME CANCERS OF THE BLADDER (PARTIAL CYSTECTOMY AND INTERSTITIAL IR-192)
    Radiotherapy and oncology
    
    M. Pernot et al., "COMBINED SURGERY AND BRACHYTHERAPY IN THE TREATMENT OF SOME CANCERS OF THE BLADDER (PARTIAL CYSTECTOMY AND INTERSTITIAL IR-192)", Radiotherapy and oncology, 38(2), 1996, pp. 115-120
53. CREW JP; OBRIEN TS; HARRIS AL
    BLADDER-CANCER ANGIOGENESIS, ITS ROLE IN RECURRENCE, STAGE PROGRESSION AND AS A THERAPEUTIC TARGET
    Cancer metastasis reviews
    
    J.P. Crew et al., "BLADDER-CANCER ANGIOGENESIS, ITS ROLE IN RECURRENCE, STAGE PROGRESSION AND AS A THERAPEUTIC TARGET", Cancer metastasis reviews, 15(2), 1996, pp. 221-230
54. NSEYO UO; LAMM DL
    THERAPY OF SUPERFICIAL BLADDER-CANCER
    Seminars in oncology
    
    U.O. Nseyo e D.L. Lamm, "THERAPY OF SUPERFICIAL BLADDER-CANCER", Seminars in oncology, 23(5), 1996, pp. 598-604
55. BADALAMENT RA; SCHERVISH EW
    BLADDER-CANCER - CURRENT DIAGNOSTIC METHODS AND TREATMENT OPTIONS
    Postgraduate medicine
    
    R.A. Badalament e E.W. Schervish, "BLADDER-CANCER - CURRENT DIAGNOSTIC METHODS AND TREATMENT OPTIONS", Postgraduate medicine, 100(2), 1996, pp. 217
56. NARAYAN P
    TRANSITIONAL-CELL CARCINOMA
    The Journal of urology
    
    P. Narayan, "TRANSITIONAL-CELL CARCINOMA", The Journal of urology, 156(2), 1996, pp. 389-390
57. LAMM DL; TORTI FM
    BLADDER-CANCER, 1996
    Ca
    
    D.L. Lamm e F.M. Torti, "BLADDER-CANCER, 1996", Ca, 46(2), 1996, pp. 93-112
58. DANUSER H; SPRINGER JP; THALMANN GN; STUDER UE
    EXPERIENCE WITH INTRAVESICAL INSTILLATION THERAPY USING OXYBUTYNIN HYDROCHLORIDE IN PATIENTS WITH DETRUSOR HYPERREFLEXIA
    Aktuelle Urologie
    
    H. Danuser et al., "EXPERIENCE WITH INTRAVESICAL INSTILLATION THERAPY USING OXYBUTYNIN HYDROCHLORIDE IN PATIENTS WITH DETRUSOR HYPERREFLEXIA", Aktuelle Urologie, 27(5), 1996, pp. 287-290
59. BOHLE A; BALCK F; VONWIESTERSHEIM J; JOCHAM D
    QUALITY-OF-LIFE AFTER INTRAVESICAL BCG-TH ERAPY
    Aktuelle Urologie
    
    A. Bohle et al., "QUALITY-OF-LIFE AFTER INTRAVESICAL BCG-TH ERAPY", Aktuelle Urologie, 27(2), 1996, pp. 79-85
60. TANAKA H; YOSHIMASA J; FURUKAWA Y; ARAI Y; ARAKI T
    INTRAVESICAL BCG-THERAPY FOR SUPERFICIAL BLADDER-CANCER - ITS EFFECTIVENESS AND ADVERSE-EFFECTS
    Aktuelle Urologie
    
    H. Tanaka et al., "INTRAVESICAL BCG-THERAPY FOR SUPERFICIAL BLADDER-CANCER - ITS EFFECTIVENESS AND ADVERSE-EFFECTS", Aktuelle Urologie, 27, 1996, pp. 51-53
61. HYACINTHE LM; JARRETT TW; GORDON CS; VAUGHAN ED; WHALEN GF
    INHIBITION OF BLADDER-TUMOR CELL IMPLANTATION IN CAUTERIZED UROTHELIUM, WITHOUT INHIBITION OF HEALING, BY A FIBRONECTIN-RELATED PEPTIDE (GRGDS)
    Annals of surgical oncology
    
    L.M. Hyacinthe et al., "INHIBITION OF BLADDER-TUMOR CELL IMPLANTATION IN CAUTERIZED UROTHELIUM, WITHOUT INHIBITION OF HEALING, BY A FIBRONECTIN-RELATED PEPTIDE (GRGDS)", Annals of surgical oncology, 2(5), 1995, pp. 450-456
62. BUYSE G; VERPOORTEN C; VEREECKEN R; CASAER P
    TREATMENT OF NEUROGENIC BLADDER DYSFUNCTION IN INFANTS AND CHILDREN WITH NEUROSPINAL DYSRAPHISM WITH CLEAN INTERMITTENT (SELF)CATHETERISATION AND OPTIMIZED INTRAVESICAL OXYBUTYNIN HYDROCHLORIDE THERAPY
    European journal of pediatric surgery
    
    G. Buyse et al., "TREATMENT OF NEUROGENIC BLADDER DYSFUNCTION IN INFANTS AND CHILDREN WITH NEUROSPINAL DYSRAPHISM WITH CLEAN INTERMITTENT (SELF)CATHETERISATION AND OPTIMIZED INTRAVESICAL OXYBUTYNIN HYDROCHLORIDE THERAPY", European journal of pediatric surgery, 5, 1995, pp. 31-34
63. VEGT PDJ; DEBRUYNE FMJ; VANDERMEIJDEN APM
    BACILLUS-CALMETTE-GUERIN IN SUPERFICIAL BLADDER-CANCER - CONSENSUS AND CONTROVERSIES
    European urology
    
    P.D.J. Vegt et al., "BACILLUS-CALMETTE-GUERIN IN SUPERFICIAL BLADDER-CANCER - CONSENSUS AND CONTROVERSIES", European urology, 27(2), 1995, pp. 89-95
64. ASO Y; AKAZA H; KOTAKE T; TSUKAMOTO T; IMAI K; NAITO S
    PREVENTIVE EFFECT OF A LACTOBACILLUS-CASEI PREPARATION ON THE RECURRENCE OF SUPERFICIAL BLADDER-CANCER IN A DOUBLE-BLIND TRIAL
    European urology
    
    Y. Aso et al., "PREVENTIVE EFFECT OF A LACTOBACILLUS-CASEI PREPARATION ON THE RECURRENCE OF SUPERFICIAL BLADDER-CANCER IN A DOUBLE-BLIND TRIAL", European urology, 27(2), 1995, pp. 104-109
65. LAMM DL
    BCG IN PERSPECTIVE - ADVANCES IN THE TREATMENT OF SUPERFICIAL BLADDER-CANCER
    European urology
    
    D.L. Lamm, "BCG IN PERSPECTIVE - ADVANCES IN THE TREATMENT OF SUPERFICIAL BLADDER-CANCER", European urology, 27, 1995, pp. 2-8
66. VANDERMEIJDEN APM
    PRACTICAL APPROACHES TO THE PREVENTION AND TREATMENT OF ADVERSE REACTIONS TO BCG
    European urology
    
    A.P.M. Vandermeijden, "PRACTICAL APPROACHES TO THE PREVENTION AND TREATMENT OF ADVERSE REACTIONS TO BCG", European urology, 27, 1995, pp. 23-28
67. SARCIA K; BALTACI S; BEDUK Y; SUZER O; KILIC S; MUFTUOGLU YZ
    EVALUATION OF CELLULAR-IMMUNITY FOLLOWING BACILLUS-CALMETTE-GUERIN THERAPY IN PATIENTS WITH SUPERFICIAL BLADDER-CANCER
    Urologia internationalis
    
    K. Sarcia et al., "EVALUATION OF CELLULAR-IMMUNITY FOLLOWING BACILLUS-CALMETTE-GUERIN THERAPY IN PATIENTS WITH SUPERFICIAL BLADDER-CANCER", Urologia internationalis, 54(3), 1995, pp. 137-141
68. HELLINGER WC; OLDENBURG WA; ALVAREZ S
    VASCULAR AND OTHER SERIOUS INFECTIONS WITH MYCOBACTERIUM-BOVIS AFTER BACILLUS OF CALMETTE-GUERIN THERAPY FOR BLADDER-CANCER
    Southern medical journal
    
    W.C. Hellinger et al., "VASCULAR AND OTHER SERIOUS INFECTIONS WITH MYCOBACTERIUM-BOVIS AFTER BACILLUS OF CALMETTE-GUERIN THERAPY FOR BLADDER-CANCER", Southern medical journal, 88(12), 1995, pp. 1212-1216
69. HOLMANG S; HEDELIN H; ANDERSTROM C; JOHANSSON SL
    THE RELATIONSHIP AMONG MULTIPLE RECURRENCES, PROGRESSION AND PROGNOSIS OF PATIENTS WITH STAGES TA AND T1 TRANSITIONAL-CELL CANCER OF THE BLADDER FOLLOWED FOR AT LEAST 20 YEARS
    The Journal of urology
    
    S. Holmang et al., "THE RELATIONSHIP AMONG MULTIPLE RECURRENCES, PROGRESSION AND PROGNOSIS OF PATIENTS WITH STAGES TA AND T1 TRANSITIONAL-CELL CANCER OF THE BLADDER FOLLOWED FOR AT LEAST 20 YEARS", The Journal of urology, 153(6), 1995, pp. 1823-1826
70. PAVLOTSKY A; EIDELMAN A; BARAK F; WALACH N; HORN Y
    LONG-TERM FOLLOW-UP OF PATIENTS WITH SUPERFICIAL TRANSITIONAL-CELL CARCINOMA OF THE URINARY-BLADDER TREATED BY INTRAVESICAL MITOMYCIN-C
    Journal of surgical oncology
    
    A. Pavlotsky et al., "LONG-TERM FOLLOW-UP OF PATIENTS WITH SUPERFICIAL TRANSITIONAL-CELL CARCINOMA OF THE URINARY-BLADDER TREATED BY INTRAVESICAL MITOMYCIN-C", Journal of surgical oncology, 60(3), 1995, pp. 191-195
71. RAITANEN MP; LUKKARINEN O
    A CONTROLLED-STUDY OF INTRAVESICAL EPIRUBICIN WITH OR WITHOUT ALPHA2B-INTERFERON AS PROPHYLAXIS FOR RECURRENT SUPERFICIAL TRANSITIONAL-CELLCARCINOMA OF THE BLADDER
    British Journal of Urology
    
    M.P. Raitanen e O. Lukkarinen, "A CONTROLLED-STUDY OF INTRAVESICAL EPIRUBICIN WITH OR WITHOUT ALPHA2B-INTERFERON AS PROPHYLAXIS FOR RECURRENT SUPERFICIAL TRANSITIONAL-CELLCARCINOMA OF THE BLADDER", British Journal of Urology, 76(6), 1995, pp. 697-701
72. LAMM DL; RIGGS DR
    IMMUNOTHERAPY OF SUPERFICIAL BLADDER-CANCER
    CLINICAL IMMUNOTHERAPEUTICS
    
    D.L. Lamm e D.R. Riggs, "IMMUNOTHERAPY OF SUPERFICIAL BLADDER-CANCER", CLINICAL IMMUNOTHERAPEUTICS, 2(5), 1994, pp. 331-341
73. HALL RR
    CURRENT ISSUES IN CANCER .4. SUPERFICIAL BLADDER-CANCER
    BMJ. British medical journal
    
    R.R. Hall, "CURRENT ISSUES IN CANCER .4. SUPERFICIAL BLADDER-CANCER", BMJ. British medical journal, 308(6933), 1994, pp. 910-913
74. BARAK M; STEIN A; MECZ Y; LURIE A; GRUENER N
    TNF AND TPS LEVELS IN FOLLOW-UP OF BCG TREATED BLADDER-CANCER PATIENTS
    Journal of tumor marker oncology
    
    M. Barak et al., "TNF AND TPS LEVELS IN FOLLOW-UP OF BCG TREATED BLADDER-CANCER PATIENTS", Journal of tumor marker oncology, 9(2), 1994, pp. 119-124
75. CONTI P; REALE M; NICOLAI M; BARBACANE RC; PLACIDO FC; IANTORNO R; TENAGLIA R
    BACILLUS-CALMETTE-GUERIN POTENTIATES MONOCYTE RESPONSES TO LIPOPOLYSACCHARIDE-INDUCED TUMOR-NECROSIS-FACTOR AND INTERLEUKIN-1, BUT NOT INTERLEUKIN-6 IN BLADDER-CANCER PATIENTS
    Cancer immunology and immunotherapy
    
    P. Conti et al., "BACILLUS-CALMETTE-GUERIN POTENTIATES MONOCYTE RESPONSES TO LIPOPOLYSACCHARIDE-INDUCED TUMOR-NECROSIS-FACTOR AND INTERLEUKIN-1, BUT NOT INTERLEUKIN-6 IN BLADDER-CANCER PATIENTS", Cancer immunology and immunotherapy, 38(6), 1994, pp. 365-371
76. SCHWAIBOLD H; KLINGENBERGER HJ; HULAND H
    LONG-TERM FOLLOW-UP OF CYTOSTATIC INTRAVE SICAL INSTILLATION USING MITOMYCIN-C AND ADRIAMYCIN IN PATIENTS WITH SUPERFICIAL BLADDER-CARCINOMA
    Der Urologe
    
    H. Schwaibold et al., "LONG-TERM FOLLOW-UP OF CYTOSTATIC INTRAVE SICAL INSTILLATION USING MITOMYCIN-C AND ADRIAMYCIN IN PATIENTS WITH SUPERFICIAL BLADDER-CARCINOMA", Der Urologe, 33(6), 1994, pp. 479-483
77. KALBLE T; BEER M; MENDOZA E; IKINGER U; LINK M; REICHERT HE; FRANGENHEIM T; KLEIN E; FABRICIUS PG
    BCG VERSUS INTERFERON-A FOR RECURRENCE PR OPHYLAXIS OF SUPERFICIAL BLADDER-CARCINOMA - A PROSPECTIVE RANDOMIZED STUDY
    Der Urologe
    
    T. Kalble et al., "BCG VERSUS INTERFERON-A FOR RECURRENCE PR OPHYLAXIS OF SUPERFICIAL BLADDER-CARCINOMA - A PROSPECTIVE RANDOMIZED STUDY", Der Urologe, 33(2), 1994, pp. 133-137
78. EROL A; OZGUR S; BASAR M; CETIN S
    TRIAL WITH BACILLUS-CALMETTE-GUERIN AND EPIRUBICIN COMBINATION IN THEPROPHYLAXIS OF SUPERFICIAL BLADDER-CANCER
    Urologia internationalis
    
    A. Erol et al., "TRIAL WITH BACILLUS-CALMETTE-GUERIN AND EPIRUBICIN COMBINATION IN THEPROPHYLAXIS OF SUPERFICIAL BLADDER-CANCER", Urologia internationalis, 52(2), 1994, pp. 69-72
79. NIKU SD; STEIN PC; SCHERZ HC; PARSONS CL
    NEW METHOD FOR CYTODESTRUCTION OF BLADDER EPITHELIUM USING PROTAMINE SULFATE AND UREA
    The Journal of urology
    
    S.D. Niku et al., "NEW METHOD FOR CYTODESTRUCTION OF BLADDER EPITHELIUM USING PROTAMINE SULFATE AND UREA", The Journal of urology, 152(3), 1994, pp. 1025-1028
80. FRIBERG S
    BCG IN THE TREATMENT OF SUPERFICIAL CANCER OF THE BLADDER - A REVIEW
    Medical oncology and tumor pharmacotherapy
    
    S. Friberg, "BCG IN THE TREATMENT OF SUPERFICIAL CANCER OF THE BLADDER - A REVIEW", Medical oncology and tumor pharmacotherapy, 10(1-2), 1993, pp. 31-36
81. OTTO T; GOEPEL M; RUBBEN H
    ADJUVANT LOCAL TREATMENT FOLLOWING CURATIVE TRANSURETHRAL RESECTION OF BLADDER-CARCINOMA
    Onkologie
    
    T. Otto et al., "ADJUVANT LOCAL TREATMENT FOLLOWING CURATIVE TRANSURETHRAL RESECTION OF BLADDER-CARCINOMA", Onkologie, 16(3), 1993, pp. 158-162
82. SCHMITZDRAGER BJ; SCHATTKA SO; EBERT T
    IMMUNOTHERAPY FOR SUPERFICIAL BLADDER-CAN CER
    Der Urologe
    
    B.J. Schmitzdrager et al., "IMMUNOTHERAPY FOR SUPERFICIAL BLADDER-CAN CER", Der Urologe, 32(5), 1993, pp. 374-381
83. KIEMENEY LALM; WITJES JA; HEIJBROEK RP; VERBEEK ALM; DEBRUYNE FMJ
    PREDICTABILITY OF RECURRENT AND PROGRESSIVE DISEASE IN INDIVIDUAL PATIENTS WITH PRIMARY SUPERFICIAL BLADDER-CANCER
    The Journal of urology
    
    L.A.L.M. Kiemeney et al., "PREDICTABILITY OF RECURRENT AND PROGRESSIVE DISEASE IN INDIVIDUAL PATIENTS WITH PRIMARY SUPERFICIAL BLADDER-CANCER", The Journal of urology, 150(1), 1993, pp. 60-64
84. DISTASI SM; VIRGILI G; VESPASIANI G; PORENA M; MICALI F
    INTRALESIONAL ALPHA-INTERFERON THERAPY IN PAPILLARY SUPERFICIAL TRANSITIONAL CELL-CARCINOMA OF THE BLADDER - A PILOT-STUDY
    British Journal of Urology
    
    S.M. Distasi et al., "INTRALESIONAL ALPHA-INTERFERON THERAPY IN PAPILLARY SUPERFICIAL TRANSITIONAL CELL-CARCINOMA OF THE BLADDER - A PILOT-STUDY", British Journal of Urology, 71(4), 1993, pp. 422-426